Oculis Holding AG (FRA:CR5) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CR5 Oculis Holding AG FRA:CR5
32 GF Score
Price €9.00
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG FFO?

FFO (Funds from operations) only applies to REITs.

FRA:CR5
32GF Score
Oculis Holding AG FRA:CR5
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
32GF Score

Get the complete analysis for FRA:CR5

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.00
Price